Eli Lilly Leverages AI to Transform Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 15 2026
0mins
Source: Fool
- AI Platform Launch: Eli Lilly launched the TuneLab platform in September last year, allowing other drugmakers digital access to proprietary data on drug molecule performance, which saves significant time and money, enabling companies to focus on their best research projects.
- Major Investment Partnership: Eli Lilly partnered with Nvidia, committing $1 billion to build a supercomputer aimed at deepening disease understanding and advancing drug development, marking a significant step in the company's AI drug development efforts.
- Huge Market Potential: According to Straits Research, the AI-powered drug discovery industry is expected to grow at an annual rate of 30% through 2034, reaching over $20 billion, providing Eli Lilly with substantial future revenue opportunities.
- Increased Collaboration Opportunities: By owning a powerful drug development platform, Eli Lilly can not only optimize its own research but also establish partnerships with smaller pharmaceutical companies, helping them bring new drugs to market and enhancing its competitive edge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 989.120
Low
950.00
Averages
1192
High
1500
Current: 989.120
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Growth Accelerates Amid High Valuation Concerns
- GLP-1 Drug Growth: Eli Lilly's GLP-1 treatments, Zepbound and Mounjaro, are in high demand, significantly boosting revenue and expected to maintain strong growth, solidifying its leadership in the global healthcare market.
- Valuation Pressure: With a market cap around $900 billion and trading at over 40 times trailing earnings, Eli Lilly's high valuation may hinder investors' ability to achieve strong returns in the future, necessitating careful risk assessment.
- New Product Launch: The company plans to launch a GLP-1 weight loss pill this year, which could add a fast-growing product to its portfolio, enhancing market competitiveness and attracting more investor interest.
- Increasing Competition: While Eli Lilly currently dominates the GLP-1 space, it may face increased competition in the future, with other healthcare companies potentially eroding its market share, making investments at such high valuations risky.
See More
Eli Lilly vs. Viking Therapeutics in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share in the weight loss drug market, bolstered by investments in manufacturing capacity and head-to-head studies showing superior weight loss efficacy compared to Novo Nordisk, solidifying its leadership in the U.S. market.
- Strong Product Performance: Lilly's Mounjaro and Zepbound achieved triple-digit revenue growth in the latest quarter, and despite an 8% drop in stock price this year, it trades at a forward P/E of 28, reflecting market confidence in its growth prospects.
- Clinical Trial Progress: Viking Therapeutics is advancing its VK2735 candidate into phase 3 trials, showing strong performance, and with demand for weight loss drugs exceeding supply, successful regulatory approval could carve out significant market share for the company.
- Potential Market Opportunity: Lilly's oral weight loss drug is under regulatory review and could be approved in the coming weeks, serving as a catalyst for its stock price, making this an opportune time for investors to consider shares in this weight loss drug leader.
See More
Hims & Hers Partners with Drugmakers to Boost Weight-Loss Market
- Stock Volatility: Hims & Hers shares are currently down 65% from their highs but surged 50% in March due to a deal with a weight-loss drugmaker, indicating market optimism about its future potential.
- Market Dominance: The weight-loss drug market is dominated by Novo Nordisk and Eli Lilly, both of which have seen revenues grow by approximately 200% over the past decade, reflecting strong demand and profitability in this sector.
- Partnership Impact: The collaboration between Hims & Hers and Novo Nordisk aims to streamline the delivery of weight-loss drugs, which is expected to boost customer demand, although Hims & Hers remains barely profitable as a drug reseller.
- Industry Outlook: Weight-loss drugs are considered the fastest-growing pharmaceutical category in history, potentially leading to significant improvements in global obesity health outcomes, and will continue to drive market performance for related drug companies in the coming years.
See More
Hims & Hers Stock Rises After Settlement with Novo Nordisk
- Settlement Impact: Hims & Hers' stock surged 50% in March following its settlement with Novo Nordisk, although it remains down 65% from its peak, indicating cautious optimism about its future prospects.
- Industry Giants' Dominance: The dominance of Novo Nordisk and Eli Lilly in the weight-loss drug market is increasingly evident, with both companies seeing approximately 200% revenue growth over the past decade, while Hims & Hers struggles with profitability as a drug reseller.
- Massive Market Potential: Weight-loss drugs are considered the fastest-growing pharmaceutical category in history, potentially leading to significant improvements in global obesity health outcomes and driving increased demand for these medications.
- Investor Focus: Although Hims & Hers was not recommended as a top investment by The Motley Fool, its partnerships with industry giants may provide support for future market performance, making it a stock worth watching for investors.
See More
US Stocks Rise Slightly Amid Oil Price Surge
- Market Performance: The S&P 500 Index rose by 0.25%, the Dow Jones Industrial Average increased by 0.10%, and the Nasdaq 100 Index climbed by 0.51%, reflecting strong performances from chipmakers and travel stocks, despite signs of a slowdown in hiring impacting market sentiment.
- Oil Price Surge: WTI crude oil prices jumped over 2% due to renewed Iranian attacks on key energy infrastructure, leading to expectations of an 8 million bpd reduction in global oil supply this month, which adds to market uncertainty and inflation concerns.
- Fed Policy Expectations: The market anticipates that the Federal Reserve will keep the federal funds target range unchanged at the upcoming FOMC meeting, even as the core PCE price index remains above target levels, indicating persistent inflationary pressures.
- Airline Stock Recovery: Delta Air Lines saw its stock rise over 6% after raising its Q1 revenue forecast, indicating signs of recovery in the airline sector amid rising fuel costs, with travel and hotel stocks also benefiting from increased bookings.
See More
AI Technology Fuels Growth for Healthcare Giants
- Eli Lilly's Growth Potential: Eli Lilly dominates the weight-loss drug market with rapidly growing revenue and earnings, having increased its dividends by 239.2% over the past decade, and while its current yield is only 0.6%, its AI initiatives are expected to accelerate drug development, enhancing profit margins and financial performance.
- Medical Device Innovation: Medtronic, a leading medical device manufacturer, is gradually implementing AI to improve product performance, such as the LINQ II cardiac monitor, which uses AI algorithms to reduce false alerts, thereby boosting market demand, although these technologies are not central to its future.
- Stable Dividend Returns: Medtronic has increased its dividends for 48 consecutive years, currently yielding 3.21%, providing a relatively low-risk investment opportunity for dividend-seeking investors, while new product launches have also driven revenue growth.
- Strategic Significance of AI: The AI applications of both Eli Lilly and Medtronic, while not core to their businesses, enhance operational efficiency and product performance, thereby strengthening their long-term growth potential in a competitive market and attracting more investor interest.
See More
Eli Lilly's Growth Accelerates Amid High Valuation Concerns
- GLP-1 Drug Growth: Eli Lilly's GLP-1 treatments, Zepbound and Mounjaro, are in high demand, significantly boosting revenue and expected to maintain strong growth, solidifying its leadership in the global healthcare market.
- Valuation Pressure: With a market cap around $900 billion and trading at over 40 times trailing earnings, Eli Lilly's high valuation may hinder investors' ability to achieve strong returns in the future, necessitating careful risk assessment.
- New Product Launch: The company plans to launch a GLP-1 weight loss pill this year, which could add a fast-growing product to its portfolio, enhancing market competitiveness and attracting more investor interest.
- Increasing Competition: While Eli Lilly currently dominates the GLP-1 space, it may face increased competition in the future, with other healthcare companies potentially eroding its market share, making investments at such high valuations risky.
See More
Eli Lilly vs. Viking Therapeutics in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share in the weight loss drug market, bolstered by investments in manufacturing capacity and head-to-head studies showing superior weight loss efficacy compared to Novo Nordisk, solidifying its leadership in the U.S. market.
- Strong Product Performance: Lilly's Mounjaro and Zepbound achieved triple-digit revenue growth in the latest quarter, and despite an 8% drop in stock price this year, it trades at a forward P/E of 28, reflecting market confidence in its growth prospects.
- Clinical Trial Progress: Viking Therapeutics is advancing its VK2735 candidate into phase 3 trials, showing strong performance, and with demand for weight loss drugs exceeding supply, successful regulatory approval could carve out significant market share for the company.
- Potential Market Opportunity: Lilly's oral weight loss drug is under regulatory review and could be approved in the coming weeks, serving as a catalyst for its stock price, making this an opportune time for investors to consider shares in this weight loss drug leader.
See More
Hims & Hers Partners with Drugmakers to Boost Weight-Loss Market
- Stock Volatility: Hims & Hers shares are currently down 65% from their highs but surged 50% in March due to a deal with a weight-loss drugmaker, indicating market optimism about its future potential.
- Market Dominance: The weight-loss drug market is dominated by Novo Nordisk and Eli Lilly, both of which have seen revenues grow by approximately 200% over the past decade, reflecting strong demand and profitability in this sector.
- Partnership Impact: The collaboration between Hims & Hers and Novo Nordisk aims to streamline the delivery of weight-loss drugs, which is expected to boost customer demand, although Hims & Hers remains barely profitable as a drug reseller.
- Industry Outlook: Weight-loss drugs are considered the fastest-growing pharmaceutical category in history, potentially leading to significant improvements in global obesity health outcomes, and will continue to drive market performance for related drug companies in the coming years.
See More
Hims & Hers Stock Rises After Settlement with Novo Nordisk
- Settlement Impact: Hims & Hers' stock surged 50% in March following its settlement with Novo Nordisk, although it remains down 65% from its peak, indicating cautious optimism about its future prospects.
- Industry Giants' Dominance: The dominance of Novo Nordisk and Eli Lilly in the weight-loss drug market is increasingly evident, with both companies seeing approximately 200% revenue growth over the past decade, while Hims & Hers struggles with profitability as a drug reseller.
- Massive Market Potential: Weight-loss drugs are considered the fastest-growing pharmaceutical category in history, potentially leading to significant improvements in global obesity health outcomes and driving increased demand for these medications.
- Investor Focus: Although Hims & Hers was not recommended as a top investment by The Motley Fool, its partnerships with industry giants may provide support for future market performance, making it a stock worth watching for investors.
See More
US Stocks Rise Slightly Amid Oil Price Surge
- Market Performance: The S&P 500 Index rose by 0.25%, the Dow Jones Industrial Average increased by 0.10%, and the Nasdaq 100 Index climbed by 0.51%, reflecting strong performances from chipmakers and travel stocks, despite signs of a slowdown in hiring impacting market sentiment.
- Oil Price Surge: WTI crude oil prices jumped over 2% due to renewed Iranian attacks on key energy infrastructure, leading to expectations of an 8 million bpd reduction in global oil supply this month, which adds to market uncertainty and inflation concerns.
- Fed Policy Expectations: The market anticipates that the Federal Reserve will keep the federal funds target range unchanged at the upcoming FOMC meeting, even as the core PCE price index remains above target levels, indicating persistent inflationary pressures.
- Airline Stock Recovery: Delta Air Lines saw its stock rise over 6% after raising its Q1 revenue forecast, indicating signs of recovery in the airline sector amid rising fuel costs, with travel and hotel stocks also benefiting from increased bookings.
See More
AI Technology Fuels Growth for Healthcare Giants
- Eli Lilly's Growth Potential: Eli Lilly dominates the weight-loss drug market with rapidly growing revenue and earnings, having increased its dividends by 239.2% over the past decade, and while its current yield is only 0.6%, its AI initiatives are expected to accelerate drug development, enhancing profit margins and financial performance.
- Medical Device Innovation: Medtronic, a leading medical device manufacturer, is gradually implementing AI to improve product performance, such as the LINQ II cardiac monitor, which uses AI algorithms to reduce false alerts, thereby boosting market demand, although these technologies are not central to its future.
- Stable Dividend Returns: Medtronic has increased its dividends for 48 consecutive years, currently yielding 3.21%, providing a relatively low-risk investment opportunity for dividend-seeking investors, while new product launches have also driven revenue growth.
- Strategic Significance of AI: The AI applications of both Eli Lilly and Medtronic, while not core to their businesses, enhance operational efficiency and product performance, thereby strengthening their long-term growth potential in a competitive market and attracting more investor interest.
See More
